Editorial: New insights into the role of complement system in liver diseases

Front Immunol. 2023 Sep 8:14:1284944. doi: 10.3389/fimmu.2023.1284944. eCollection 2023.

Zhenya Guo^{1

2

3}, Xiude Fan⁴, Laura E Nagy⁵, Stephen Tomlinson⁶, Guandou Yuan^{1

2

3}

¹ Division of Hepatobiliary Surgery, the First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.
² Key Laboratory of Early Prevention and Treatment for Regional High Frequency Tumor (Guangxi Medical University), Ministry of Education, Nanning, Guangxi, China.
³ Guangxi Key Laboratory of Immunology and Metabolism for Liver Diseases, Guangxi Medical University, Nanning, Guangxi, China.
⁴ Department of Endocrinology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China.
⁵ Northern Ohio Alcohol Center, Department of Inflammation and Immunity, Cleveland Clinic, Cleveland, OH, United States.
⁶ Department of Microbiology and Immunology, Medical University of South Carolina, Charleston, SC, United States.

No abstract available

Keywords: antibody-mediated rejection; complement; hepatocellular carcinoma; ischemia-reperfusion injury; nonalcoholic fatty liver disease.

Publication types